While yet another study shows psilocybin’s efficacy in treating depression in cancer patients, and 2024 presidential candidates push for a psychedelics reform from all sides, Colorado public health officials fight over manure.
As MDMA nears FDA approval, LSD’s efficacy in treating generalized anxiety disorder is demonstrated in MindMed’s Phase 2b study. Meanwhile, Congress has approved a psychedelic treatment bill for active duty service members suffering from PTSD.
The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a “both and” approach to treating ADHD.
Psilocybin can be an useful tool when it comes to reducing nicotine withdrawal, PTSD, and even OCD symptoms. It could also be a hazardous weapon for those who suffer from personality disorders.
While everyone was preparing to head to Wonderland Miami, the psychedelic space saw a week full of debates! From the FDA’s recommendation to limit psychological support in clinical trials, to debates over the necessity of the ‘trip’ in the psychedelic experience, to whether microdosing’s benefits are influenced by expectancy bias.
While unprecedented positive results provide further proof of psilocybin’s anti-depressive effects, other studies investigate the long-term adverse effects of challenging trips. Meanwhile, the DEA wants to increase the manufacturing of certain psychedelics yet again as more psychedelic dispensaries are getting raided in Canada.
As researchers investigate the potential of psilocybin in cancer patients and LSD as treatment for ADHD, the psychedelic ecosystem witnesses more acquisitions, patents, and decriminalization efforts. However, the space also sees reprimands for abuse by therapists and a pilot attributing almost shutting off plane engines to a “nervous breakdown” caused by shrooms.
This week’s psychedelic news roundup includes psilocybin’s potential to treat fibromyalgia, studies on predictors of the intensity of a trip and more.
Weekly psychedelic news: Psychedelics could treat OCD, Novartis abandons study and Cybin Inc moves to acquire Small Pharma
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.